Nature.comBitter CRISPR patent war intensifiesNature.comAt stake are intellectual-property rights to the use of CRISPR–Cas9 gene-editing tools in eukaryotes, organisms such as plants and animals. This would include applications of the technique to trea… Continue reading
Nature.comBitter CRISPR patent war intensifiesNature.comAt stake are intellectual-property rights to the use of CRISPR–Cas9 gene-editing tools in eukaryotes, organisms such as plants and animals. This would include applications of the technique to trea… Continue reading
The EconomistGene editing takes another step forwardThe EconomistAnd another enzyme, Cpf1, is growing rapidly in popularity as a substitute for Cas9 in conjunction with CRISPR. The researchers who have developed base editing even dream of reaching into… Continue reading
Genetic Literacy ProjectUnapproved stem cell therapy leaves elderly women blindGenetic Literacy Project[E]ye doctors based primarily at the Bascom Palmer Eye Institute in Miami had published a widely covered report describing three eerily similar cases… Continue reading
PLoS Blogs (blog) |
What Should Gene Therapy Cost?
PLoS Blogs (blog) By the time that the FDA’s advisory committee gave a near-instantaneous and unanimous thumbs-up for gene therapy to treat a form of hereditary blindness on October 12, tears were freely flowing. Fittingly, it was World Sight Day. The new drug, Luxturna … |
PharmaTimes |
Shire’s haemophilia A gene therapy wins Orphan status
PharmaTimes Shire’s gene therapy candidate SHP654, an investigational factor VIII gene therapy for the treatment of haemophilia A, has been awarded Orphan Drug Designation by US regulators. The move qualifies Shire for access to various incentives designed to … |